Arterial hypertension and β-amyloid accumulation have spatially overlapping effects on posterior white matter hyperintensity volume: A cross-sectional study

Study design

We used baseline MRI, CSF AD biomarkers, cognitive performance scores, medical records and longitudinal cognitive performance scores from the DELCODE (DZNE Longitudinal Cognitive Impairment and Dementia Study) cohort, an observational multicentre study from the German Centre for Neurodegenerative Diseases (DZNE) that focuses on the multimodal assessment of preclinical and clinical AD stages [16]. All participants received an extensive assessment at the local study site prior to joining DELCODE, which included medical history, psychiatric and neurological examination, neuropsychological testing, blood laboratory work-up, and routine MRI in accordance with local standards. All memory clinics used the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) neuropsychological test battery [17] to assess cognitive function. We focused on non-complaining healthy controls with normal cognition (NC) and participants with SCD and MCI and excluded patients with dementia due to AD to enrich our sample by variance due to vascular disease and Aβ pathology.

The presence of SCD and amnestic MCI was diagnosed using the existing research criteria for SCD [18,19] and MCI [20], respectively. Participants were diagnosed with SCD if they reported subjective cognitive decline or memory concerns, as expressed to the physician of the memory centre, and had a test performance better than −1.5 standard deviations (SD) below the age, sex, and education-adjusted normal performance on all subtests of the CERAD battery. The MCI group consisted of participants with amnestic MCI, as defined by age, sex, and education-adjusted performance below −1.5 SD on the delayed recall trial of the CERAD word-list episodic memory tests.

The NC group was recruited through local newspaper advertisements. Individuals who responded to the advertisement were screened by telephone with regard to SCD. The control group had to achieve unimpaired cognitive performance according to the same definition as the SCD group.

All participants entered DELCODE based on either their clinical diagnosis derived from the clinical workup or their identification as a control subject according to the procedures outlined. Additional inclusion criteria for all groups were age[≥[60 years, fluent German language skills, capacity to provide informed consent, and presence of a study partner. The main exclusion criteria for all groups were conditions clearly interfering with participation in the study or the study procedures, including significant sensory impairment. The following medical conditions were considered exclusion criteria: current major depressive episode, major psychiatric disorders either at baseline or in the past (e.g., psychotic disorder, bipolar disorder, substance abuse), neurodegenerative disorder other than AD, vascular dementia, history of stroke with residual clinical symptoms, history of malignant disease, severe or unstable medical conditions, and clinically significant laboratory abnormalities in vitamin B12. Prohibited drugs included chronic use of psychoactive compounds with sedative or anticholinergic effects, use of anti-dementia agents in SCD, amnestic MCI, and control subjects, and investigational drugs for the treatment of dementia or cognitive impairment one month before entry and throughout the duration of the study.

All participants gave written informed consent before inclusion in the study. DELCODE is retrospectively registered at the German Clinical Trials Register (DRKS00007966, 04/05/2015) and was approved by ethical committees and local review boards.

Hypertension

Medical records were retrospectively screened for cardiovascular risk factors at the time of MRI. Patients diagnosed before to have primary or secondary arterial hypertension were considered to suffer from arterial hypertension (1: hypertensive; 0: normotensive). Single blood pressure measurements were not taken into account since repeated, long-term or at-home measurements would be required for the final diagnosis [21].

Cognitive performance

All participants underwent a rich neuropsychological assessment, comprising the Mini-Mental State Examination (MMSE), Alzheimer’s Disease Assessment Scale–Cognitive 13-item subscale (ADAS-Cog 13), the Free and Cued Selective Reminding Test (FCRST; including a serial subtraction task, Wechsler Memory Scale revised version (WMS-R), Logical Memory [Story A] and Digit Span), two semantic fluency tasks (animals and groceries), the Boston Naming Test (15-item short version analogue to the CERAD battery, supplemented by five infrequent items from the long version), the oral form of the Symbol-Digit-Modalities Test (including a subsequent free recall of symbols and symbol-digit pairings), Trail Making Test Parts A and B, Clock Drawing and Clock Copying, a recall task of previously copied figures (as in the CERAD test battery), the Face Name Associative Recognition Test, and a Flanker task to assess executive control of attention. We focused on memory and executive function at baseline derived from these neuropsychological tests using confirmatory factor analysis to reduce the influence of test-specific effects and measurement errors [22].

We also leveraged the Preclinical Alzheimer’s Disease Cognitive Composite (PACC5) [23], which provides a single outcome measure reflective of episodic memory, timed executive function, and global cognition; domains that have been found sensitive to amyloid pathology. The PACC5 score was calculated as the mean of an individual’s z-standardised performance in the FCSRT Free Recall and Total Recall, the MMSE, the WMS-R Logical Memory Story A Delayed Recall, the Symbol-Digit-Modalities Test, and the sum of the two category fluency tasks and used the baseline mean and SD values of the cognitively unimpaired group of our sample to derive the subtest z-scores.

We selected subjects with available PACC5 scores over three annual follow-ups for further analysis. We estimated rates of change in these PACC5 scores over time using a linear mixed effect model (ΔPACC5 from hereon). We expressed it as follows: where PACC5_ij is the PACC5 scores of subject i ∈ [1, N] at visit j ∈ [1, t]; X_ij ∈ ℝ^N×p a matrix of the p predictor variables; β ∈ ℝ^p a vector of fixed-effects regression coefficients; Z_ij ∈ ℝ^N×q a design matrix for the q random effects; b_ij∈ ℝ^q a vector of random effects; and ϵ_ij the within-subject measurement errors. The fixed effects structure include clinical group structure measured at baseline and their corresponding interaction with time (t_ij).The fixed effects include age, sex and education taken at baseline.

Structural MRI

Structural MRI scans were acquired at nine German DZNE sites on Siemens MR scanners (including three TIM Trio, four Verio, one Skyra, and one Prisma system). We used T1-weighted MPRAGE images (3D GRAPPA PAT 2, 1 mm³ isotropic, 256 × 256, 192 sagittal slices, repetition time 2500 ms, echo time 4.33 ms, inversion time 1100 ms, flip angle 7°, ∼5 min acquisition time) and T2-weighted 3D FLAIR images (GRAPPA PAT factor 2, 1 mm³ isotropic, 256 × 256, 192 sagittal slices, repetition time 5000 ms, echo time 394 ms, inversion time 1800 ms, ∼7 min acquisition time). Standard operating procedures, quality assurance and assessment were provided and supervised by the DZNE imaging network (iNET, Magdeburg) as described in [16]. We computed the mean background intensity as a surrogate measure of image quality and motion artefacts [24,25] and adjusted statistical models for it, as the quality of the scans determine also segmentation performance [26–28].

Biomarker characterisation

Trained study assistants carried out lumbar punctures for 49% of all DELCODE participants. CSF samples were centrifuged, aliquoted and stored at −80°C for retests. Biomarkers known to mirror AD pathology (CSF Aβ42 and Aβ40) were determined by commercially available kits (V-PLEX Aβ Peptide Panel 1 (6E10) Kit (K15200E)). Each participant was classified as normal (-) or abnormal (+) with regard to amyloid levels based on the Aβ42/40 ratio, independently of their phosphorylated Tau (pTau) status, in line with the ATN classification system. Cut-offs (Aβ negative: Aβ42/40 >0.08; Aβ positive: Aβ42/40 ≤ 0.08) were calculated from DELCODE using the Gaussian mixture modelling in the R-package flexmix (v2.3-15) (for details see [16,29]).

WMH segmentation and spatial processing

We processed baseline T1-weighted and FLAIR scans as follows. We performed bias field inhomogeneity correction, skull stripping, and segmentation using the Multi-Brain (MB) toolbox in statistical parametric mapping (SPM) [30]. We segmented grey matter (GM), white matter (WM), and CSF from T1-weighted scans with MB and identified WMH probability maps from FLAIR scans using the Lesion Prediction Algorithm in the Lesion Segmentation Toolbox [31]. We then used MB for normalising tissue classes (and WMH maps) to a DELCODE-specific MB template. We adjusted for local volume changes introduced by the normalisation in GM and WMH probability maps by modulation with Jacobian determinants [30,32]. Finally, we smoothed WMH maps with Gaussian kernels (6 mm full width at half maximum). Processing results of all steps were carefully checked visually and statistically using covariance-based tools provided in Computational Anatomy Toolbox 12 (CAT12) [33].

ROI-based processing

We extracted WMH volume from 12 regions of interest (ROI) in cerebral WM, as described in detail in a previous study [11]. In brief, we created ROIs in accordance with the STRIVE criteria [34] and included the four lobes of the brain, four major WM tracks and three sections of the corpus callosum and a global cerebral WM mask. We calculated WMH volumes for each ROI and adjusted for total intracranial volume (TICV). All computations were conducted in the template space.

A schematic overview both processing and analysis methods is illustrated in Figure S1.

Statistical analyses

Mediation models

Assuming that long-term exposure to hypertension and Aβ build-up has a negative effect on the integrity of the white matter and that its damage—depicted in the form of regional WMH—impacts cognition negatively, we hypothesise that there is an indirect effect of hypertension and Aβ on cognition that is mediated by WMH volume, in line with theoretical considerations [5,6,40,41] (Figure 1). We used the R-package lavaan (v0.6-11) and followed the steps for mediation analysis suggested by Hair et al. [42] Significance was assessed using 95% confidence intervals generated by bias-corrected bootstrap with 1000 replicates.

• Download figure
• Open in new tab

Figure 1. Model investigating direct and indirect (via WMH) effects of hypertension and Aβ positivity on cognition.

Here we seek to understand whether subjects with arterial hypertension or Aβ positive status have worse cognitive performance at baseline (baseline memory, executive function, and PACC5 scores) and outcomes over time (ΔPACC5). Because both the Aβ and vascular pathologies may exacerbate the formation of WMH and these, in turn, may also contribute to brain dysfunction and poor cognitive outcomes [5,6,40,41], we also test for an indirect mediating effect of hypertension and Aβ positivity on cognitive performance via regional WMH volumes. We adjusted such models for age, sex, education, mean background intensity, and TICV, as described in ‘Covariates, confounders, and data transformation’.

Sample description

We included baseline data of 375 subjects out of 1079 recruited for DELCODE after quality control and assessing the availability of CSF biomarkers and MRI (Figure S2; median age 70.0 [IQR 66.0-74.0] years, 46.9% female, median years of education 13 [IQR 12-17]; European origins). ΔPACC5 was only available for a subset (n=226/375). Demographics and global WMH volumes stratified by hypertension and Aβ positivity are summarised in Table 1. We found no significant association between arterial hypertension and Aβ positivity (Χ2=2.1302, p=0.1444).

WMH are associated with both arterial hypertension and Aβ positivity

We initially investigated WMH in relation to hypertension and Aβ positivity. We observed that the global volume of WMH was a fourth greater in subjects with either a history of hypertension vs normotension (26% [95%-CI 5%, 52%]) or a positive vs negative Aβ status (25% [95%-CI 3%, 52%]) (Table 2). Regional variations in the frontal, parietal, and occipital—not temporal—lobes contributed to this outcome; regression coefficients for both hypertension and Aβ positivity were comparable in these three regions (Table 2). In posterior regions of the brain, we found that the relationship between WMH and hypertension was clearer than that between WMH and Aβ positivity in the splenium of the corpus callosum (Figure 2 and Table 2); the opposite was true in the optic radiation (Figure 2 and Table 2; peak: between forceps major and inferior fronto-occipital fasciculus).

• Download figure
• Open in new tab

Figure 2. Posterior WMH probability is associated with both history of arterial hypertension and Aβ positivity.

Analysis. We examined the relationship between WMH segmentation maps (outcome) and arterial hypertension and Aβ positivity (factors) at a voxel level via 2×2 ANCOVA. We accounted for the effects of age, sex, education, mean background intensity, and total intracranial volume. We used an explicit mask to constrain the analysis to voxels in which data for at least five patients were available. Illustration. Glass brain projections display regions where we found evidence for a link between WMH probability and hypertension and Aβ positivity (top and middle rows, respectively). In the bottom row, we coloured regions blue if T values for hypertension were greater than for Aβ positivity and gold otherwise. We thresholded contrast maps at 5% and adjusted p-values for FDR. Findings. Subjects with hypertension had significantly greater WMH volumes throughout the whole brain than those with normotension (peak: superior longitudinal fasciculus, xyz_MNI = [32, −1, 18], T = 3.88, DoF = [1.0, 367.0], p_FDR = 0.015). Moreover, WMH volume was significantly higher in subjects Aβ positivity versus negativity in posterior regions of the brain, particularly in segments of the forceps major and inferior fronto-occipital fasciculus (xyz_MNI = [30, −58, 4], T = 5.20, DoF = [1.0, 367.0], p_FDR = 0.001).

WMH are negatively associated with cognitive performance and outcomes

We then investigated whether cognitive performance and outcomes were associated with WMH (Figure 3 and Table 3). We found a significant association between global WMH volumes and worse baseline cognitive performance and a sharper cognitive decline over the course of three years, regardless of hypertension diagnosis and Aβ positivity (Table 3). Evidence for such a connection was present in most regions of interest, except in the external capsule. Such relationships were consistently evident around portions of the anterior thalamic radiation neighbouring the thalamus (Figure 3). In frontal and occipital regions, we also saw a significant link between WMH and quicker cognitive deterioration (Figure 3 - frontal peak at the level of the genu of the corpus callosum; occipital peak at the level of the forceps major and inferior fronto-occipital longitudinal fasciculus).

• Download figure
• Open in new tab

Figure 3. WMH volume is associated with worse baseline cognitive performance and accelarated decline over time.

Analysis. We used multiple linear regression with WMH segmentation maps as the dependent variable and cognitive performance as the independent variable. We accounted for the effects of hypertension, Aβ positivity, age, sex, education, mean background intensity, and total intracranial volume. We used an explicit mask to constrain the analysis to voxels in which data for at least five patients were available. We thresholded contrast maps at 5% and adjusted p-values for FDR. Illustration. Regression results with memory (top left), executive function (bottom left), PACC5 (top right), and ΔPACC5 (bottom right) as independent variables. Findings. We found WMH to be significantly associated with worse cognitive performance at baseline and sharper decline within a three-year period. Such relationships were consistently evident around portions of the anterior thalamic radiation neighbouring the thalamus (memory: xyz_MNI = [−8, −1, 3], T = 7.00, DoF = [1.0, 366.0], p_FDR = 1.44×10⁻⁵; executive: xyz_MNI = [−9, 0, 5], T = 6.74, DoF = [1.0, 366.0], p_FDR = 2.85×10⁻⁵; PACC5: xyz_MNI = [−8, 1, 4], T = 7.20, DoF = [1.0, 366.0], p_FDR = 8.43×10⁻⁶; ΔPACC5: xyz_MNI = [−7, 2, 2], T = 4.53, DoF = [1.0, 217.0], p_FDR = 5.12×10⁻³). Frontal and occipital WMH also coincided with a faster cognitive decline (frontal peak at the level of the genu of the corpus callosum: xyz_MNI = [−1, 23, 4], T = 5.19, DoF = [1.0, 217.0], p_FDR = 1.37×10⁻³; occipital peak at the level of the forceps major and inferior fronto-occipital longitudinal fasciculus: xyz_MNI = [17, −81, 2], T = 4.69, DoF = [1.0, 217.0], p_FDR = 1.23×10⁻²).

The effect of Aβ positivity on cognition does not depend on WMH, but that of hypertesion does

Our final assessment consisted of determining whether Aβ positivity or hypertension were associated with cognition (Table 4). Despite the lack of evidence for a direct association between hypertension and cognitive performance, we found hypertension to be indirectly linked to both worse performance at baseline and a steeper deterioration over the course of three years via splenial WMH (regression coefficient ± standard error; memory: −0.05±0.02, p_FDR=0.029; executive: −0.04±0.02, p_FDR=0.067; PACC5: −0.05±0.02, p_FDR=0.030; ΔPACC5: −0.09±0.03, p_FDR=0.043). On the other hand, the association between Aβ positivity and baseline and longitudinal cognitive performance (memory: −0.33±0.08, p_FDR<0.001; executive: −0.21±0.08, p_FDR<0.001; PACC5: −0.29±0.09, p_FDR=0.006; ΔPACC5: −0.34±0.04, p_FDR<0.05) was independent of its association with regional WMH volumes (no grounds for mediation in general, as shown in Table 2).